IL190779A0 - Compositions for treatment of eye diseases - Google Patents

Compositions for treatment of eye diseases

Info

Publication number
IL190779A0
IL190779A0 IL190779A IL19077908A IL190779A0 IL 190779 A0 IL190779 A0 IL 190779A0 IL 190779 A IL190779 A IL 190779A IL 19077908 A IL19077908 A IL 19077908A IL 190779 A0 IL190779 A0 IL 190779A0
Authority
IL
Israel
Prior art keywords
compositions
treatment
eye diseases
diseases
eye
Prior art date
Application number
IL190779A
Original Assignee
Lycored Ltd
Sela Yoram
Zohar Nir
Sharoni Yoav
Levy Joseph
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lycored Ltd, Sela Yoram, Zohar Nir, Sharoni Yoav, Levy Joseph filed Critical Lycored Ltd
Priority to IL190779A priority Critical patent/IL190779A0/en
Publication of IL190779A0 publication Critical patent/IL190779A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL190779A 2005-10-16 2008-04-10 Compositions for treatment of eye diseases IL190779A0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL190779A IL190779A0 (en) 2005-10-16 2008-04-10 Compositions for treatment of eye diseases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL17145205 2005-10-16
PCT/IL2006/001168 WO2007046083A2 (en) 2005-10-16 2006-10-05 Compositions for treatment of eye diseases
IL190779A IL190779A0 (en) 2005-10-16 2008-04-10 Compositions for treatment of eye diseases

Publications (1)

Publication Number Publication Date
IL190779A0 true IL190779A0 (en) 2009-02-11

Family

ID=37962894

Family Applications (1)

Application Number Title Priority Date Filing Date
IL190779A IL190779A0 (en) 2005-10-16 2008-04-10 Compositions for treatment of eye diseases

Country Status (7)

Country Link
EP (1) EP1937240A2 (en)
JP (1) JP2009515821A (en)
AU (1) AU2006305546A1 (en)
IL (1) IL190779A0 (en)
MX (1) MX2008004981A (en)
RU (1) RU2008119234A (en)
WO (1) WO2007046083A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101254818B1 (en) 2004-11-09 2013-04-15 쿠프론 인코포레이티드 Methods and materials for skin care
WO2008108825A2 (en) * 2006-10-10 2008-09-12 Burnham Institute For Medical Research Neuroprotective compositions and methods
DE202007012373U1 (en) * 2007-09-04 2009-01-08 Omnivision Gmbh Dietary supplements, sachets containing a dietary supplement and use of a dietary supplement
WO2010060729A1 (en) * 2008-11-03 2010-06-03 Giuliani S.P.A. Therapeutic, dietary, or cosmetic use of compounds with specific anti-apoptotic activity toward caspase-3, and compositions containing these compounds
BRPI1005154A2 (en) * 2009-01-19 2018-02-06 Lycored Ltd "therapeutic composition, method for inhibiting or reducing the production of superoxide ions, nitric oxide (n), tumor necrosis factor alpha (tnf-alpha) and / or prostaglandin e2 (pge2) in a mammalian subject, methods of treatment and use of a combination"
WO2011076869A1 (en) * 2009-12-22 2011-06-30 Aakerlund Hans-Erik Isolated green plant material
JP2011256118A (en) * 2010-06-07 2011-12-22 Kao Corp Il-8 and gm-csf expression inhibitor
US20140065196A1 (en) * 2010-10-04 2014-03-06 Cupron, Inc. Cosmetic skin care compositions
EP2731595B1 (en) * 2011-07-13 2019-09-04 University Of Georgia Research Foundation, Inc. Use of xanthophyll carotenoids to improve visual performance and neural efficiency
CN103798808A (en) * 2012-11-15 2014-05-21 中国科学院大连化学物理研究所 Nutrient formula and application thereof to food or medicine for reliving asthenopia
AP2017009684A0 (en) * 2014-08-11 2017-01-31
JP6817951B2 (en) * 2014-11-25 2021-01-20 ライコード・リミテツド Bioactive tomato composition with a small amount of lycopene
JP7105532B2 (en) * 2017-05-10 2022-07-25 ロート製薬株式会社 Composition for prevention, improvement or treatment of posterior segment disease
WO2019021299A1 (en) * 2017-07-25 2019-01-31 Tathagata Dutta A topical ocular suspension of antioxidants
WO2019087189A1 (en) * 2017-11-01 2019-05-09 Lycored Ltd. A method for improving ocular blood flow
US11696593B2 (en) 2018-08-24 2023-07-11 Bioscience Formulators, LLC Astaxanthin nutritional compositions and uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103756A (en) * 1999-08-11 2000-08-15 Vitacost Inc. Ocular orally ingested composition for prevention and treatment of individuals
US6573299B1 (en) * 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye

Also Published As

Publication number Publication date
WO2007046083A3 (en) 2011-05-19
JP2009515821A (en) 2009-04-16
EP1937240A2 (en) 2008-07-02
MX2008004981A (en) 2008-10-17
WO2007046083A2 (en) 2007-04-26
RU2008119234A (en) 2009-11-27
AU2006305546A1 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
IL190779A0 (en) Compositions for treatment of eye diseases
IL186578A0 (en) Compositions for treatment of neovascularization diseases
HK1222537A1 (en) Liquid formulations for treatment of diseases or conditions
IL191283A (en) Compositions for the treatment of ophthalmic disorders
EP2187743A4 (en) Formulations for treatment of ocular diseases or conditions
SI2444079T1 (en) Compositions and Methods for Treatment of Eye Disorders
EP2083862A4 (en) Compositions and methods for treating ocular diseases and conditions
EP1871331A4 (en) Composition for treatment of menopause
HK1201046A1 (en) Methods of treating ophthalmic diseases
PT2056863T (en) Treatment of ocular diseases
ZA200903862B (en) Nutritional supplement composition for treatment of ocular diseases
EP2060264A4 (en) Agent for treating eye diseases
GB0909297D0 (en) Composition for the treatment of skin conditions
GB0523961D0 (en) The treatment of ophthalmic diseases
EP1988889A4 (en) Compositions and methods for treatment of ophthalmic diseases and disorders
HU0500145D0 (en) Composition for the treatment of oral diseases
EP1865952A4 (en) Histamine-containing composition for the treatment of allergic diseases
EP2361627A4 (en) Composition for prevention or treatment of eye diseases
GB0523964D0 (en) The treatment of ophthalmic diseases
HU0500947D0 (en) Composition for treatment of paradontosis
GB0623740D0 (en) Treatment of disease
HUP0500948A2 (en) Composition for treatment of diabeticus paradontosis
ZA200904660B (en) Treatment of IL-1-Beta related diseases
TWI350171B (en) Pharmaceutical compositions for treatment of cardio-cerebral-vascular diseases
GB0523962D0 (en) The treatment of ophthalmic diseases